Advertisement

Topics

European Adopts Positive Opinion For Gilead???s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes

20:00 EDT 22 Jun 2017 | BioSpace

Vosevi is Gileads Fourth Sofosbuvir-Based Treatment to Receive CHMP Positive Opinion for the Treatment of Chronic HCV Infection FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products...

Original Article: European Adopts Positive Opinion For Gilead???s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes

NEXT ARTICLE

More From BioPortfolio on "European Adopts Positive Opinion For Gilead???s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...